ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer cell death. Sirtuin 2 (SIRT2), a member of cla...

Full description

Saved in:
Bibliographic Details
Published inAntioxidants Vol. 9; no. 11; p. 1137
Main Authors Wang, Wenyu, Im, Jihye, Kim, Soochi, Jang, Suin, Han, Youngjin, Yang, Kyung-Min, Kim, Seong-Jin, Dhanasekaran, Danny N., Song, Yong Sang
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.11.2020
MDPI
Subjects
Apoptosis
Cancer therapies
Cell cycle
Cell death
chemoresistance
Chemotherapy
Cisplatin
Health aspects
Histones
Homeostasis
Medical prognosis
NAD
Ovarian cancer
Oxidative stress
Patients
Physiological aspects
Plasmids
Platinum
Proteins
Reactive oxygen species
ROS
SIRT2
Statistical analysis
Tumor cell lines
Up-regulation
South Korea
Australia
United States > US
Japan
Online AccessGet full text

Cover

More Information
Summary:Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer cell death. Sirtuin 2 (SIRT2), a member of class III NAD+ dependent histone deacetylases (HDACs), has been reported to be involved in regulating cancer hallmarks including drug response. In this study, we aimed to identify the role of SIRT2 in oxidative stress and cisplatin response in cancer. Two ovarian cancer cell lines featuring different sensitivities to cisplatin were used in this study. We found different expression patterns of SIRT2 in cisplatin-sensitive (A2780/S) and cisplatin-resistant (A2780/CP) cancer cells with cisplatin treatment, where SIRT2 expression was augmented only in A2780/S cells. Furthermore, cisplatin-induced ROS generation was responsible for the upregulation of SIRT2 in A2780/S cells, whereas overexpression of SIRT2 significantly enhanced the sensitivity of cisplatin-resistant counterpart cells to cisplatin. Our study proposes that targeting SIRT2 may provide new strategies to potentiate platinum-based chemotherapy in ovarian cancer patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2076-3921
2076-3921
DOI:10.3390/antiox9111137